Radiopharmaceutical developer Cell>Point of Englewood, CO, has named former Philips Medical Systems chief medical officer Dr. David Rollo as its president.
Cell>Point has licensed five radiopharmaceutical technology platforms from the University of Texas M. D. Anderson Cancer Center in Houston, and plans to apply for U.S. Food and Drug Administration approval of its first universal oncology molecular imaging agent, 99mTc-EC-DG (technetium-99m-ethylenedicysteine-deoxyglucose) in 2007.
The firm said the product is the first oncology imaging agent designed to image certain cancers and cardiovascular diseases on existing SPECT gamma cameras.
The company said it will also begin clinical trials on its first oncology intracellular therapeutic, rhenium-188/cold rhenium-ethylenedicysteine-deoxyglucose (188Re/cold Re-EC-DG). Rollo will direct Cell>Point in the conduct of the therapeutic trial and the next seven radiodiagnostic and therapeutic trials slated for 2007, according to the developer.
By AuntMinnie.com staff writers
September 13, 2006
Related Reading
Biotech firm Cell>Point sees promise for oncology SPECT, May 20, 2005
Philips adds molecular imaging partnership, September 29, 2003
Copyright © 2006 AuntMinnie.com
